Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Timed PD-1 blockade synergizes with IL-7/CCL19 armoring to reverse CAR-T exhaustion in PD-L1-high large B-cell lymphoma

Lixia Sheng, Wen Lei, Duo Wu, Yi Zhang, Yanli Lai, Shuyan Wang, Duobing Zou, Ping Zhang, Kaihong Xu, Shanhao Tang, Huijie Hu, Tongyu Li, Qitian Mu, Xiaofei Ye, Hui Liu, Wenbin Qian, Guifang Ouyang

Blood (2025) 146 (Supplement 1): 1929.

https://doi.org/10.1182/blood-2025-1929

Published: 2025

Journal Articles

FOXO1⁺themis⁺ memory t cells underpin long-term remission after cytokine-armored CD19 CAR-t therapy in refractory lymphoma

Wenbin Qian, Aiqi Zhao, Hui Liu, Wen Lei, Minghuan Zhang, Tianshu Yu, Shuhan Zhong

Blood (2025) 146 (Supplement 1): 3707.

https://doi.org/10.1182/blood-2025-3707

Published: 2025

Journal Articles

Integrated genomic and tumor microenvironment subtyping refines risk stratification in primary central nervous system lymphoma

Xianggui Yuan, Qian Luo, Yurong Huang, Chaoyi Li, Teng Yu, Shanshan Guo, Qunyi Guo, Xueli Jin, Jiefeng Tong, Aiqi Zhao, Wen Lei, Xian Li, Baizhou Li, Shumei Wei, Wenbin Qian, Yun Liang

Blood (2025) 146 (Supplement 1): 5304.

https://doi.org/10.1182/blood-2025-5304

Published: 2025

Journal Articles

The prognostic value of CAR-hematox in predicting toxic events in patients with relapsed refractory B cell lymphoma receiving 7x19 CAR-T treatment

Wenbin Qian, Panpan Chen, Hui Liu, Wen Lei

Blood (2025) 146 (Supplement 1): 7687.

https://doi.org/10.1182/blood-2025-7687

Published: 2025

Journal Articles

Long-Term Efficacy and Safety of CD19-Specific CAR-T Cells Armed with IL-7 and CCL19 in Patients with Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center Prospective Study

Wenbin Qian, Hui Liu, Wen Lei, Linqin Wang, Panpan Chen

Blood (2024) 144 (Supplement 1): 2087.

https://doi.org/10.1182/blood-2024-205376

Published: 2024

Journal Articles

Safety and Feasibility of a 41BB Co-Stimulated CD19 CAR-NK Cell Therapy in Refractory/Relapsed Large B-Cell Lymphoma

Wenbin Qian, Wen Lei, Hui Liu, Wei Chen, Yun Liang, Yi Eve Sun, Xiangmin Tong, Aibin Liang

Blood (2024) 144 (Supplement 1): 7209.

https://doi.org/10.1182/blood-2024-202988

Published: 2024

Journal Articles

CD27-Armored BCMA-CAR T Cell (CBG-002) Therapy for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial

Yang Xu, Xuzhao Zhang, Dijia Xin, Jiawei Zhang, Luyao Wang, Yili Fan, Boxiao Chen, Wen Lei, Xi Qiu, Huawei Jiang, Xibin Xiao, Liansheng Huang, Wenjun Yang, Jiangao Zhu, Wenbin Qian

Blood (2023) 142 (Supplement 1): 3468.

https://doi.org/10.1182/blood-2023-174364

Published: 2023

Journal Articles

A Phase 1 Study of RJMty19: Anti-CD19 Humanized CAR-Engineered Allogeneic Double Negative T Cells in Adults with B-Cell Non-Hodgkin's Lymphoma

Xibin Xiao, Wen Lei, Huawei Jiang, Xi Qiu, Xian Li, Panpan Chen, Yang Xu, Haicun Xie, Guangrong Song, Yu Cheng, Fuqiang Wu, Daqing Liu, Liming Yang, Wenbin Qian

Blood (2023) 142 (Supplement 1): 2094.

https://doi.org/10.1182/blood-2023-189149

Published: 2023

Journal Articles

Safety and Feasibility of Anti-CD19 CAR-T Expressing IL-7 and CCL19 in Patients with Relapsed or Refractory Large B-Cell Lymphoma

Wen Lei, Zhao Ai, Hui Liu, Chunmei Yang, Cheng Wei, Shanshan Guo, Zhilu Chen, Qunyi Guo, Linjie Li, Mingzhe Zhao, Gongqiang Wu, Jinyi Zhang, Jimin Gao, Wenbin Qian

Blood (2022) 140 (Supplement 1): 12722.

https://doi.org/10.1182/blood-2022-156635

Published: 2022

Journal Articles

Safety and Efficacy of CD19 CAR-T Cells Co-Expressing IL-7 and CCL19 in Combination with Anti-PD-1 Antibody for Refractory/Relapsed DLBCL: Preliminary Data from the Phase Ⅰb Trial (NCT04381741)

Wenbin Qian, Aiqi Zhao, Hui Liu, Wen Lei, Yun Liang, Xianggui Yuan

Blood (2021) 138 (Supplement 1): 3843.

https://doi.org/10.1182/blood-2021-144523

Published: 2021

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Timed PD-1 blockade synergizes with IL-7/CCL19 armoring to reverse CAR-T exhaustion in PD-L1-high large B-cell lymphoma

FOXO1⁺themis⁺ memory t cells underpin long-term remission after cytokine-armored CD19 CAR-t therapy in refractory lymphoma

Integrated genomic and tumor microenvironment subtyping refines risk stratification in primary central nervous system lymphoma

The prognostic value of CAR-hematox in predicting toxic events in patients with relapsed refractory B cell lymphoma receiving 7x19 CAR-T treatment

Long-Term Efficacy and Safety of CD19-Specific CAR-T Cells Armed with IL-7 and CCL19 in Patients with Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center Prospective Study

Safety and Feasibility of a 41BB Co-Stimulated CD19 CAR-NK Cell Therapy in Refractory/Relapsed Large B-Cell Lymphoma

CD27-Armored BCMA-CAR T Cell (CBG-002) Therapy for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial

A Phase 1 Study of RJMty19: Anti-CD19 Humanized CAR-Engineered Allogeneic Double Negative T Cells in Adults with B-Cell Non-Hodgkin's Lymphoma

Safety and Feasibility of Anti-CD19 CAR-T Expressing IL-7 and CCL19 in Patients with Relapsed or Refractory Large B-Cell Lymphoma

Safety and Efficacy of CD19 CAR-T Cells Co-Expressing IL-7 and CCL19 in Combination with Anti-PD-1 Antibody for Refractory/Relapsed DLBCL: Preliminary Data from the Phase Ⅰb Trial (NCT04381741)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only